Combination of multiple myeloma and primary myelofibrosis with transformation to acute myeloid leukemia (review and case report)



Cite item

Full Text

Abstract

Review and case report of a patient with simultaneously developed lymphoid and myeloid hemoblastosis is presented. Diagnosis of multiple myeloma and primary myelofibrosis are confirmed by complete blood count, myelogramm, trephinebiopsy, immunohistochemical, cytogenetic, biochemical and radiological examination. Complete remission of multiple myeloma was achieved after 7 courses «VAD» and 11-week treatment with recombinant erythropoietin beta with subsequent maintenance therapy course of bortezomib and reaferon. However, primary myelofibrosis was progressed to acute myeloid leukemia. Disease's progression was delayed with 3 therapy courses «5+2». But 3 months later hemorrhagic syndrome appeared and patient died.

Full Text

Restricted Access

About the authors

N A Romanenko

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

Email: rom-nik@yandex.ru; RNIIHT@mail.ru; bloodscience@mail.ru

S S Bessmeltsev

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

V I Rugal

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

N A Potichonova

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

M N Zenina

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

K M Abdulkadyrov

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico- biological Agency, St. Petersburg

References

  1. Абдулкадыров К.М. Хронический идиопатический миелофиброз // Клиническая гематология: Справочник / Под ред. К.М. Абдулкадырова. СПб.: Питер, 2006. С. 181-186.
  2. Андреева Н.Е. Миеломная болезнь // Руководство по гематологии: в 2 т. Т. 1 / Под ред. А.И. Воробьева. 2-е изд., перераб. и доп. М.: Медицина, 1985. С. 292-308.
  3. Андреева Н.Е., Балакирева Т.В. Множественная миелома // Руководство по гематологии: в 3 т. Т. 2 / Под ред. А.И. Воробьева. 3-є изд., перераб. и доп. М.: Ныодиамед, 2003. С. 151-173.
  4. Бессмельцев С.С. Хронический идиопатический миелофиброз // Гематология: Новейший справочник / Под общ. ред. К.М. Абдулкадырова. М.: Экс- мо; СПб.: Сова, 2004. С. 556-571.
  5. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы, 2007. 480 с.
  6. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома // Гематология: Новейший справочник / Под общ. ред. К.М. Абдулкадырова. М.: Экс- мо; СПб.: Сова, 2004. С. 593-665.
  7. Вотякова О.М., Демина Е.А. Множественная миелома // Клиническая онкогематология: Руководство для врачей / Под ред. М.А. Волковой. М.: Медицина, 2007. С. 847-873.
  8. Демидова А.В. Хронический идиопатический миелофиброз // Клиническая онкогематология: Руководство для врачей / Под ред. М.А. Волковой. М.: Медицина, 2007. С. 616-630.
  9. Созин С.Е., Салогуб Г.Н. Случай развития острого мегакариобластного лейкоза (М7) у больной с клинической ремиссией множественной миеломы // Клин, онкогематол. 2008. № 2. С. 141-144.
  10. Abildgaard N., Bendix-Hansen К., Kristensen J.E. et al. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum // Br. J. Haematol. 1997. Vol. 99. №3. P.641-648.
  11. Blade J., Samson D., Reece D. et al. On behalf of Myeloma Subcommittee of the EBMT (European Grop for Blood and Marrow Transplantation), Chronic Leucaemia Working Party and the Myeloma Working Committee of the IBMTR (Intarnational Bone Marrow Transplant Registry, and ABMTR (Autologous Blood and MaiTOw Transplant Registry) // Br. J. Haematol. 1998. Vol. 102. № 5. P. 1115-1123.
  12. Cervantes F., Alvarez-Larran A., Hernandez-Boluda J.C. et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia // Br. J. Haematol. 2006. Vol. 134. № 2. P. 184-186.
  13. Colagrande M., Di Ianni M., Coletti G. et al. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving, thalidomide therapy // Int. J. Hema- tol. 2009. Vol. 89. № 1. P. 76-79.
  14. de la Serna J., Bomstein R., Lahuerta-Palacios J.J. The use of an expanded circulating hematopoietic progenitor cell pool associated with bone marrow fibrosis for the support of autologous transplantation in IgD multiple myeloma // Bone Marrow Transplant. 1997. Vol. 19. № 10. P. 1033-1036.
  15. Diihrsen U., Uppenkamp M., Meusers P. et al. Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias // Blut. 1988. Vol. 56. № 3. P. 97-102.
  16. Etienne A., Gruson B., Chatelain D. et al. Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review // Advances in Hematol. 2009. Vol. 2009. P. 5.
  17. Groga G.M., Van Camp B., Kyle R.A. et al. Plasma cell neoplasms / E.S. Jaffe, N.L. Harris, Y. Stein et al. (eds) // Pathology and Genetics: Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001. P. 142-156.
  18. Huang Y.W. et al. Current drug therapy for multiple myeloma // Drugs. 1999. Vol. 57. № 4. P. 485.
  19. Jimenez-Zepeda V.H., Dominguez-Martinez V.J. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis // Int. J. Hematol. 2009. Vol. 89. № 3. P. 259-268.
  20. Jimenez-Zepeda V.H., Dominguez-Martinez V.J. Plasma cell leukemia: a rare condition // Ann. Hematol. 2006. Vol. 85. № 4. P. 263-267.
  21. Kanoh T, Okuma M. IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist // Rinsho Ketsueki. 1996. Vol. 37. № 3. P. 244-248.
  22. Kato М., Umeda М., Kosuge Т. ct al. Idiopathic myelofibrosis transformed to acute myelomono- cytic leukemia associated with non-Hodgkin’s lymphoma // Rinsho Ketsueki. 1994. Vol. 35. №6. P. 581-587.
  23. Kawauchi K., Mori H., Sugiyama H. et al. Multiple myeloma with coexistent myelofibrosis: Improvement of myelofibrosis following recovery from multiple myeloma after treatment with melphalan and prednisolon // Jpn. J. Med. 1991. Vol. 30. № 5. P. 483^186.
  24. Kikukawa M., Umahara T., Kikawada M. et al. Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor // Geriatr. Gerontol. Int. 2009. Vol. 9. № 4. P. 395- 398.
  25. Krzyzaniak R.L., Buss D.H., Cooper M.R., Wells H.B. Marrow fibrosis and multiple myeloma //Am. J. Clin. Pathol. 1988. Vol. 89. № 1. P. 63-68.
  26. Kubota Y., Waki M. Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia // Rinsho Ketsueki. 2009. Vol. 50. № 3. P. 197-202.
  27. Laszlo J., Huang A.T. // Saminars Hemat. 1975. ѴЫ. 2. P. 403.
  28. Massa F.S., Rolon J.M., Pavlovsky S. Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin’s lymphoma who underwent autologous hematopoietic stem cell transplantation // Hematology. 2007. Vol. 12. № 6. P. 487-488.
  29. Mastunaga T., Takemoto N., Miyaima N. et al. Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta //Ann. Hematol. 2004. Vol. 83. № 5. P. 322- 325.
  30. Matsui K., Adachi M., Tominaga T. et al. Angioim- munoblastic T cell lymphoma associated with reversible myelofibrosis // Intern. Med. 2008. ѴЫ. 47. № 21. P. 1921-1924.
  31. Me Cluggage W.G., Jones F.G, Hull D. et al. Sclerosing IgA multiple myeloma //Acta Haematol. 1995. ѴЫ. 94. №2. P.98-101.
  32. Mittelman M. The implications of anemia in multiple myeloma // Clin. Lymphoma. 2003. Vol. 4 (Suppl. 1). S23-29.
  33. Mittelman M., Zeidman A., Kanter P. et al. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies // Eur. J. Haematol. 2004. Vol. 72. № 3. P. 155-165.
  34. Murayama T., Matsui T., Hayashi Y. et al. Plasma cell leukemia with myelofibrosis//Ann. Hematol. 1994. Vol. 69. №3. P. 151-152.
  35. Nakase K., Hasegawa M., Susuki Y. et al. Myelofibrosis complicated by T-cell lymphoma followed by leukemic transformat// Rinsho Ketsueki. 1995. Vol. 36. № 11. P. 1284-1288.
  36. Orth T., Treichel U., Mayet W.J. et al. Reversible myelofibrosis in angioimmunoblastic lymphadenopathy // Dtsch Med Wochenschr. 1994. Vol. 119. № 19. P. 694-698.
  37. Rao S.A., Gottesman S.R., Nguyen M.C. et al. T cell lymphoma associated with myelofibrosis // Leuc. Lymphoma. 2003. Vol. 44. № 4. P. 715-718.
  38. Sever M., Jorgensen J.L., Gurevich I. et al. Primary myelofibrosis with concurrent precursor T- cell lymphoblastic lymphoma of the spleen in a 26- year-old patient // Leuc. Res. 2009. Vol. 33. № 11. P. 186-188.
  39. Stevenson J.P., Schwarting R., Schuster S.J. Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis // Am. J. Hematol. 1998 Vol. 59. № 1. P. 79-82.
  40. Subramanian R., Basu D., Dutta T.K. Significance of bone marrow fibrosis in multiple myeloma // Pathology. 2007. Vol. 39. № 5. P. 512-515.
  41. Takada M., Umeda M., Shikoshi K., Shirai T. IgG lambda-type multiple myeloma associated with myelofibrosis accompanied by thrombocytosis // Rinsho Ketsueki. 1991. Vol. 32. Ns 9. P. 1001-1005.
  42. Tefferi A., Silversttein M.N. Recombinant human erythropoietin therapy in patient with myelofibrosis with myeloid metaplasia // Br. J. Haematol. 1994. Vol. 41. P. 893.
  43. Vandermolen L., Rice L., Lynch E.C. Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome // Am. J. Med. 1985. Vol. 79. № 3. P. 297-302.
  44. Vardiman J.M., Thiele Juergen, Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes // Blood. 2009. Vol. 114. №5. P.937-951.
  45. Vedrine L., Boucher E., Samson T. et al. Mieloid pseudo-splenomegaly in patient with a myeloma // Press. Med. 2002. Vol. 31. P. 1846-1848,
  46. Zhang Y., Li L., Nie L. et al. Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders // Zhonghua Xue Ye Xue Za Zhi. 2008. Vol. 29. № 2. P. 105-109.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Romanenko N.A., Bessmeltsev S.S., Rugal V.I., Potichonova N.A., Zenina M.N., Abdulkadyrov K.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies